Kymera Therapeutics (KYMR) Competitors $46.20 +2.72 (+6.26%) Closing price 09/11/2025 04:00 PM EasternExtended Trading$46.17 -0.03 (-0.06%) As of 07:50 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KYMR vs. QGEN, BBIO, MRNA, VRNA, ELAN, ROIV, RVMD, GRFS, RYTM, and LEGNShould you be buying Kymera Therapeutics stock or one of its competitors? The main competitors of Kymera Therapeutics include QIAGEN (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry. Kymera Therapeutics vs. Its Competitors QIAGEN BridgeBio Pharma Moderna Verona Pharma PLC American Depositary Share Elanco Animal Health Roivant Sciences Revolution Medicines Grifols Rhythm Pharmaceuticals Legend Biotech Qiagen (NYSE:QGEN) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment. Is QGEN or KYMR more profitable? Qiagen has a net margin of 18.30% compared to Kymera Therapeutics' net margin of -616.03%. Qiagen's return on equity of 14.77% beat Kymera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Qiagen18.30% 14.77% 8.87% Kymera Therapeutics -616.03%-31.60%-27.12% Which has higher valuation & earnings, QGEN or KYMR? Qiagen has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQiagen$1.98B5.18$83.59M$1.6927.25Kymera Therapeutics$47.07M70.18-$223.86M-$3.47-13.31 Which has more risk and volatility, QGEN or KYMR? Qiagen has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.17, suggesting that its share price is 117% more volatile than the S&P 500. Do analysts rate QGEN or KYMR? Qiagen presently has a consensus target price of $49.69, suggesting a potential upside of 7.87%. Kymera Therapeutics has a consensus target price of $58.76, suggesting a potential upside of 27.20%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kymera Therapeutics is more favorable than Qiagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qiagen 0 Sell rating(s) 8 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.27Kymera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 15 Buy rating(s) 2 Strong Buy rating(s) 3.06 Does the media prefer QGEN or KYMR? In the previous week, Qiagen had 2 more articles in the media than Kymera Therapeutics. MarketBeat recorded 14 mentions for Qiagen and 12 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 1.25 beat Qiagen's score of 1.00 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 6 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of QGEN or KYMR? 70.0% of Qiagen shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryQiagen beats Kymera Therapeutics on 9 of the 17 factors compared between the two stocks. Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KYMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KYMR vs. The Competition Export to ExcelMetricKymera TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.11B$3.15B$5.78B$10.07BDividend YieldN/A2.32%5.69%4.62%P/E Ratio-13.3121.6075.1126.20Price / Sales70.18297.80470.8391.87Price / CashN/A45.3337.0859.91Price / Book3.589.7112.116.28Net Income-$223.86M-$53.33M$3.29B$270.85M7 Day Performance6.18%1.04%1.58%3.58%1 Month Performance15.88%9.93%7.88%6.67%1 Year Performance3.31%13.80%61.66%27.73% Kymera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KYMRKymera Therapeutics2.7001 of 5 stars$46.20+6.3%$58.76+27.2%+3.2%$3.11B$47.07M-13.31170Positive NewsQGENQIAGEN4.4438 of 5 stars$46.53+0.9%$49.69+6.8%+3.3%$10.34B$1.98B27.495,765Positive NewsBBIOBridgeBio Pharma4.3446 of 5 stars$51.76-1.5%$62.18+20.1%+87.9%$9.89B$221.90M-12.66400Positive NewsMRNAModerna4.5286 of 5 stars$24.09-1.6%$42.88+78.0%-68.1%$9.37B$3.24B-3.205,800Positive NewsVRNAVerona Pharma PLC American Depositary Share2.1875 of 5 stars$105.91+0.0%$109.00+2.9%+252.9%$9.16B$42.28M-106.9830Positive NewsELANElanco Animal Health2.807 of 5 stars$18.38-0.4%$17.33-5.7%+29.8%$9.12B$4.44B21.379,000High Trading VolumeROIVRoivant Sciences2.8249 of 5 stars$11.93-0.1%$16.50+38.3%+16.4%$8.15B$29.05M-17.04860News CoverageOptions VolumeRVMDRevolution Medicines4.2575 of 5 stars$37.97-0.9%$69.92+84.2%+11.0%$7.10B$11.58M-8.44250Trending NewsAnalyst ForecastAnalyst RevisionGap UpGRFSGrifols3.8709 of 5 stars$9.97+1.0%$10.30+3.3%+9.0%$6.85B$7.81B8.5223,822News CoveragePositive NewsRYTMRhythm Pharmaceuticals3.1918 of 5 stars$103.15-1.0%$101.57-1.5%+98.6%$6.85B$130.13M-34.27140Positive NewsLEGNLegend Biotech3.2909 of 5 stars$34.73+1.0%$74.22+113.7%-32.0%$6.41B$627.24M-39.472,609Positive News Related Companies and Tools Related Companies QGEN Competitors BBIO Competitors MRNA Competitors VRNA Competitors ELAN Competitors ROIV Competitors RVMD Competitors GRFS Competitors RYTM Competitors LEGN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KYMR) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTrump’s new AI budget just passed — one stock could soarIn a quiet move few people noticed... President Trump just green-lit what could become the biggest AI budge...Behind the Markets | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KYMR Stock Alerts